North Carolina-based BioDelivery Sciences said this week that outside researchers have used its Bioral drug-delivery technology to deliver siRNAs targeting H5N1 avian influenza genes both intravenously and intranasally into a mouse model.
The work, which was conducted by an undisclosed “commercial collaborator,” marks BioDelivery’s most mature effort to date to apply its technology to the burgeoning RNAi drugs sector.
Get the full story with
GenomeWeb Premium
Only $95 for the
first 90 days*
GenomeWeb Premium gives you:
✔ Full site access
✔ Interest-based email alerts
✔ Access to archives
Never miss another important industry story.
Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.
*Before your trial expires, we’ll put together a custom quote with your long-term premium options.
Not ready for premium?
Register for Free ContentYou can still register for access to our free content.